Phase 2 “proof-of-concept” study evaluating aviptadil for treatment of COVID-induced Acute Respiratory Distress Syndrome (ARDS) to be initiated

The phase 2 study will include patients with COVID-19 who otherwise have less than a 50% chance of survival.

Source:

Biospace Inc.